ciglitazone has been researched along with Multiple Sclerosis in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Schmidt, S | 1 |
Moric, E | 1 |
Schmidt, M | 1 |
Sastre, M | 1 |
Feinstein, DL | 1 |
Heneka, MT | 1 |
Niino, M | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability[NCT00242177] | Phase 1 | 30 participants | Interventional | 2003-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for ciglitazone and Multiple Sclerosis
Article | Year |
---|---|
Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
Topics: Animals; Anti-Inflammatory Agents; Encephalomyelitis, Autoimmune, Experimental; Humans; Multiple Scl | 2007 |
1 other study available for ciglitazone and Multiple Sclerosis
Article | Year |
---|---|
Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Cell Divi | 2004 |